The 24th International AIDS Conference (AIDS 2022), 29 July-2 August 2022, Montreal, Canada and virtually

第 24 届国际艾滋病大会 (AIDS 2022)，2022 年 7 月 29 日至 8 月 2 日，加拿大蒙特利尔

• 批准号: 10481133
• 负责人: Christopher C. Beyrer
• 金额: $ 88.5万
• 依托单位: IAS
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-19 至 2023-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10481133
• 关键词: 2019-nCoV; AIDS prevention; AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Address; Advocate; Affect; Antiviral Therapy; Area; Attention; Basic Science; Behavioral Research; COVID-19; COVID-19 pandemic; COVID-19 pandemic effects; COVID-19 vaccine; Canada; Caring; Child; Clinical Research; Communities; Consensus; Country; Data; Development; Discipline; Discrimination; Disease Progression; Disease remission; Economics; Environment; Epidemic; Epidemiology; Face; Financial Support; Fostering; Goals; HIV; HIV Infections; HIV vaccine; HIV/TB; Health; Health system; Homophobia; Human Rights; Hybrids; Immunization; Impairment; Incidence; Indigenous; Injectable; International; International AIDS; Intervention; Investments; Knowledge; Laws; Lead; Leadership; Learning; Life Expectancy; Modeling; Monitor; Morbidity - disease rate; Oral; Outcome; Participant; Pathogenesis; Persons; Policies; Politics; Prevention; Prevention approach; Preventive vaccine; Privatization; Research; Research Design; Research Personnel; Resources; Risk; SARS-CoV-2 infection; Science; Science Policy; Scientist; Services; Social Behavior; System; Technology; Telemedicine; Training; Translational Research; Travel; United Nations; Update; Vaccines; Viral hepatitis; Work; Youth; co-infection; community based participatory research; comorbidity; criminal behavior; design; economic determinant; health disparity; illicit drug use; implementation barriers; implementation research; implementation science; innovation; low and middle-income countries; marginalized population; multidisciplinary; neglect; next generation; novel; pandemic disease; pandemic preparedness; patient oriented; person centered; prevent; programs; racial and ethnic disparities; response; same-sex partnership; service delivery; sex; social; social stigma; success; symposium; synergism; transmission process; transphobia; virtual

Project Summary The advances in HIV science across the past 40 years have been remarkable, with near normal life expectancy for persons on antiviral therapy and ever widening access to prevention, treatment and care. However, we do not have an effective HIV vaccine or a cure for the 37 million people living with HIV infection worldwide. The June 2021 United Nations Political Declaration on HIV and AIDS sets new targets and offers welcome clarity on the breadth of policy interventions and resource investments required to meet these objectives. But these will only become a reality if evidence informs policy and scientific innovation continues to provide ever better solutions to remaining biomedical, socio-behavioral and implementation challenges. A global convening bringing together scientists, clinicians, affected community leadership, implementers, donors, and political leaders is thus urgently needed to critically define future research agendas, shift new evidence to action and chart a new consensus on achieving the still elusive goal of pandemic control of HIV. The theme of AIDS 2022, “Re-engage & follow the science” epitomizes this urgency. Recognizing that uneven rollout of COVID-19 vaccines will likely prevent many key stakeholders particularly from countries with a high burden of HIV from travelling internationally, AIDS 2022 will be a fully hybrid conference (29 July-2 August 2022). In addition to the virtual conference platform, Montreal will provide a compelling venue for AIDS 2022 as a leading center of HIV science, with a view to the progressive Canadian policy environment for those at risk and in recognition of Canadian leadership in global cooperation to address the epidemic. Specific aims for AIDS 2022 are to: 1. Accelerate scientific discovery to drive innovation across the HIV prevention and treatment cascades, including pathogenesis, transmission, vaccines, remission and a functional cure; long-acting oral and injectable treatment and prevention technologies, including rings for prevention; integrated and differentiated models of care; and analyses of structural and economic determinants of health. 2. Accelerate updates to treatment guidance especially for low and middle-income countries, infected children and persons with HIV, TB, viral hepatitis and COVID-19 infection. 3. Facilitate the adaptation of innovations from the response to COVID-19 across science, policy and practice and consolidating good practice for pandemic preparedness, and immunization efforts including new partnerships between public and private stakeholders and learnings from adaptations from the HIV response that accelerated the response to COVID-19. 4. Advance core components of implementation science research that address the challenges and opportunities of integration across a range of epidemic settings and in the COVID-19 era, including findings from community-led research, monitoring and innovations in service delivery, including telemedicine. 5. Address HIV vulnerability and determinants of disease progression among key and marginalized populations, including novel interventions and implementation science to reduce stigma and discrimination, including intersectional stigmas of HIV, homophobia, transphobia, and ethnic and racial disparities, including those among indigenous/first nation communities and impact of criminalization of behaviours including same- sex relationships, illicit drug use, and sex work. 6. Draw attention to enduring gaps in the HIV response, such as areas where greater investment is needed in research and person-centered service delivery, and where the needs of communities remain neglected. The scientific program will consist of six tracks: Track A/Basic and Translational Research; Track B/Clinical Research; Track C/Epidemiology and Prevention Science; Track D/Social and Behavioral Research; Track E/ Implementation Research, Economics, Systems and Synergies with other Health and Development Sectors; and Track F/Political research, law, policy and human rights. While the scientific program of the conference is developed by international track committees that represent different disciplines and areas of science, cross- cutting aspects will be covered in plenary talks that also connect the scientific tracks with community and leadership perspectives. Additionally, bridging sessions are designed to cut across at least two of the scientific tracks to provide opportunities for multi-disciplinary, multi-perspective dialogues, often using interactive formats. The participation of young researchers, basic scientists and researchers in related fields such as non- communicable diseases will be strengthened by active solicitation of relevant science and the provision of specific financial support, in addition to remote-access options. Key science from the conference will be disseminated and discussed in regional contexts following AIDS 2022.

项目摘要 在过去的40年里，艾滋病毒科学取得了令人瞩目的进步，人们的预期寿命接近正常水平 对于接受抗病毒治疗的人，并不断扩大获得预防、治疗和护理的机会。然而，我们有 没有有效的艾滋病毒疫苗，也没有治愈全世界3700万艾滋病毒感染者的方法。这个 2021年6月，联合国关于艾滋病毒和艾滋病的政治宣言设定了新的目标，并为 实现这些目标所需的政策干预和资源投资的广度。但这些人会 只有当证据为政策提供信息，科学创新继续提供更好的信息时，才能成为现实 解决仍然存在的生物医学、社会行为和实施挑战。一场全球性的会议带来了 因此，科学家、临床医生、受影响的社区领导层、实施者、捐赠者和政治领导人 迫切需要批判性地定义未来的研究议程，将新的证据转化为行动，并制定新的 就实现艾滋病毒大流行控制这一仍然难以实现的目标达成共识。艾滋病2022年的主题是“重新参与” &跟上科学“就是这种紧迫性的缩影。 认识到新冠肺炎疫苗的不均衡推出可能会阻止许多关键利益攸关方，特别是 来自国际旅行的艾滋病毒高负担国家，艾滋病2022将是一个完全混合的会议 (2022年7月29日至8月2日)除了虚拟会议平台外，蒙特利尔还将提供一个引人注目的会场 为2022年艾滋病作为领先的艾滋病毒科学中心，以期为加拿大提供进步的政策环境 对于那些面临风险的人，并承认加拿大在全球合作应对这一流行病方面的领导作用。 2022年艾滋病的具体目标是： 1.加快科学发现，推动艾滋病毒预防和治疗级联的创新， 包括发病机制、传播、疫苗、缓解和功能治疗；长效口服和 可注射治疗和预防技术，包括用于预防的环；综合和差异化 保健模式；以及对健康的结构和经济决定因素的分析。 2.加快更新治疗指南，特别是针对受感染的低收入和中等收入国家 儿童和艾滋病毒、结核病、病毒性肝炎和新冠肺炎感染者。 3.促进应对新冠肺炎的创新在科学、政策和社会各领域的适应 实践和巩固大流行防备和免疫工作的良好做法，包括新的 公共和私营利益攸关方之间的伙伴关系和从艾滋病毒应对措施中吸取的经验教训 这加速了对新冠肺炎的回应。 4.推进执行科学研究的核心组成部分，以应对挑战和 跨一系列疫情背景和新冠肺炎时代的融合机会，包括调查结果 来自社区领导的研究、监测和服务提供方面的创新，包括远程医疗。 5.在关键和边缘化群体中解决艾滋病毒脆弱性和疾病进展的决定因素 人口，包括减少耻辱和歧视的新干预措施和实施科学， 包括对艾滋病毒、同性恋恐惧症、变性人恐惧症以及族裔和种族差异的跨部门污名，包括 土著/第一民族社区之间的冲突和行为犯罪化的影响-- 性关系、非法吸毒和性工作。 6.提请注意艾滋病毒防治工作中的持久差距，例如需要更多投资的领域 在研究和以人为中心的服务提供方面，以及社区的需求仍然被忽视的地方。 科学计划将包括六个轨道：轨道A/基础和转化研究；轨道B/临床 研究；C类/流行病学和预防科学；D类/社会和行为研究；E类 执行研究、经济、系统以及与其他卫生和发展部门的协同作用；以及 F/政治研究、法律、政策和人权。而大会的科学计划是 由代表不同学科和科学领域的国际跟踪委员会开发，交叉- 削减方面将在全体会议上讨论，这些会议还将科学轨道与社区和 领导力视角。此外，桥接会议旨在跨越至少两个科学 为多学科、多视角的对话提供机会，通常采用互动形式。 青年研究人员、基础科学家和非政府组织等相关领域研究人员的参与 将通过积极征集相关科学知识和提供 除远程访问选项外，还提供具体的财务支持。这次会议的主要科学成果将是 在2022年艾滋病后的区域范围内传播和讨论。